Posted in | News | Nanomedicine | Nanobusiness

EORTC-NCI-AACR Symposium to Feature BIND Therapeutics’ Presentation on Clinical Activity of BIND-014

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that a poster presentation including Phase 2 clinical data on its lead drug candidate, BIND-014, in patients with non-small cell lung cancer (NSCLC) will be presented at the upcoming 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.

The meeting, which is hosted by the European Organization for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), takes place November 18-21, 2014, in Barcelona, Spain.

BIND-014 is a PSMA targeted polymeric nanoparticle containing the cytotoxic agent docetaxel. In preclinical cancer models, BIND-014 was shown to increase accumulation of docetaxel in tumors which translated to marked improvements in antitumor activity. In a Phase 1 study, BIND-014 was well tolerated and showed initial indications of anti-tumor activity. BIND-014 is currently in two Phase 2 trials for the treatment of non-small cell lung cancer and metastatic castrate resistant prostate cancer.

Details of the poster presentation at EORTC-NCI-AACR:

  • (Abstract #41 ): Wednesday, November 19, 2014, through Friday November 20, 2014, from 9:00 a.m. to 4:00 p.m. GMT, Title: “Clinical activity of BIND-014 (docetaxel nanoparticles for injectable suspension) as second-line therapy in patients (pts) with Stage III/IV non-small cell lung cancer,” J. Summa, BIND Therapeutics, Poster Board #035, Session: Cytotoxics, Location: Exhibition Hall.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.